Lynx1 Capital Management LP

Lynx1 Capital Management LP has filed trades across 5 companies (mainly through SEC (Form 4)), most often in TScan Therapeutics, Inc., Passage BIO, Inc. and Cullinan Therapeutics, Inc. Over a trading history stretching from 31 May 2023 to 10 August 2026, the count stands at 33 filings.

Market trades split into 30 purchases (€18.9M) and 3 sales (€60k). Taken together, the purchases exceed the sales by €18.9M. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. So far in 2026, the count stands at 3 purchases and no sales.

Half of the purchases are above €129k and half below. Clusters matter here: 1 out of 30 purchases overlapped with buying by a colleague within 30 days. When several insiders buy within a few weeks of each other, analysts speak of a cluster purchase. After 11 purchases with a full 90-day history, the hit rate stands at 82% and the median 90-day move at +33.9%. These figures describe past trades and do not predict future prices.

The newest entry dates from 13 August 2026: an open-market purchase of €51k, in Korro Bio, Inc. Typically, a trade is published a median of 2 days after it takes place. US insiders must file a Form 4 within two business days of a trade. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.